Administering Axatilimab: From Order to Observation

This segment walks through the practical mechanics of delivering infusion-based therapy in chronic GVHD, using axatilimab as the model. Faculty describe the full pathway: entering the weight-based order, securing insurance approval, building the plan with pharmacy, and delivering the initial infusions at the treating center before considering any transition. The infusion itself is brief, but faculty allot additional time for labs and post-infusion observation. Monitoring is detailed, including hepatic parameters, CPK, amylase, and lipase, with a cadence that tightens early and spaces out once patients stabilize, and transient low-grade abnormalities often resolve without intervention. Keeping patients at the center through the early doses is grounded in infusion-reaction timing, which clusters in the first several treatments. The segment then turns to extended-interval dosing, reviewing the limited monthly data that showed no new safety signal but unestablished efficacy, and the resulting caution against spacing out treatment too early.